Abstract 196P
Background
High-grade serous ovarian carcinoma (HGSOC) remains the deadliest gynecologic malignancy, primarily due to its asymptomatic nature in the early-stages and the complex, poorly understood mechanisms driving its progression.
Methods
In this study, we employed single-cell RNA-seq analysis to delve deeper into early-stage of HGSOC, uncovering a previously underappreciated dominant infiltration and heterogeneity of regulatory T (Treg) cells.
Results
Within the HGSOC lesions, we detected CD4 regulatory T cells (Tregs) displaying diverse transcriptomic profiles indicative of their naïve, effector, proliferating, and destabilized states. The presence of Tregs was associated with an immunosuppressive tumor microenvironment, featured by CD4 Th2 cells, exhausted CD8 T cells, lacking cytotoxicity NK cells, and tumor-associated macrophages (TAMs). Cell-to-cell communication analysis predicted Treg-mediated inhibition of immune responses and reciprocal interactions with tumor cells promoting Treg activation. Trajectory analysis revealed two Treg differentiation paths, both leading to immunosuppressive FOXP3high and FOXP3+ Treg profiles. Notably, while the trajectory of FOXP3high profile converges with proliferating Tregs, the second path of cytotoxic FOXP3+ Tregs aligned with FOXP3- ex-Tregs, distinguished by an anti-tumor CXCL13+IFNG+ transcriptomic profile.
Conclusions
Therefore, despite the immunosuppressive environment, we identified the counteracting antitumor activity of Tregs, highlighting the potential of manipulating Treg cell fate as for therapeutic strategies.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session